• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    6/8/23 9:07:16 AM ET
    $ACON
    $AKYA
    $CPHI
    $EVAX
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $ACON alert in real time by email

    Gainers

    • Aclarion (NASDAQ:ACON) stock increased by 38.5% to $1.44 during Thursday's pre-market session. The company's market cap stands at $11.3 million.
    • China Pharma Holding (AMEX:CPHI) stock moved upwards by 13.22% to $0.45. The company's market cap stands at $4.3 million.
    • Evaxion Biotech (NASDAQ:EVAX) shares rose 13.04% to $1.56. The market value of their outstanding shares is at $41.2 million.
    • NanoVibronix (NASDAQ:NAOV) stock moved upwards by 12.87% to $3.92. The company's market cap stands at $6.5 million.
    • MSP Recovery (NASDAQ:LIFW) shares rose 12.45% to $0.54. The company's market cap stands at $39.8 million.
    • 4D Molecular Therapeutics (NASDAQ:FDMT) shares increased by 12.2% to $20.5. The market value of their outstanding shares is at $858.1 million.

    Losers

    • Precipio (NASDAQ:PRPO) shares decreased by 26.5% to $0.5 during Thursday's pre-market session. The market value of their outstanding shares is at $11.7 million.
    • BiomX (AMEX:PHGE) stock decreased by 11.4% to $0.32. The company's market cap stands at $14.5 million.
    • Landos Biopharma (NASDAQ:LABP) shares declined by 9.79% to $3.19. The company's market cap stands at $9.9 million.
    • PolarityTE (NASDAQ:PTE) shares decreased by 9.59% to $0.26. The company's market cap stands at $1.9 million.
    • Akoya Biosciences (NASDAQ:AKYA) shares fell 9.0% to $5.06. The company's market cap stands at $194.3 million.
    • Werewolf Therapeutics (NASDAQ:HOWL) stock declined by 7.98% to $3.11. The market value of their outstanding shares is at $110.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON
    $AKYA
    $CPHI
    $EVAX

    CompanyDatePrice TargetRatingAnalyst
    Evaxion A/S
    $EVAX
    2/19/2026$10.00Buy
    Maxim Group
    4D Molecular Therapeutics Inc.
    $FDMT
    1/28/2026$33.00Overweight
    Barclays
    Werewolf Therapeutics Inc.
    $HOWL
    12/19/2025$1.00Outperform → Neutral
    Wedbush
    4D Molecular Therapeutics Inc.
    $FDMT
    11/7/2025Underweight → Equal-Weight
    Morgan Stanley
    4D Molecular Therapeutics Inc.
    $FDMT
    1/13/2025$40.00 → $15.00Outperform → Market Perform
    BMO Capital Markets
    4D Molecular Therapeutics Inc.
    $FDMT
    11/21/2024$8.00Underweight
    Morgan Stanley
    Akoya BioSciences Inc.
    $AKYA
    11/15/2024$7.00 → $5.00Buy → Hold
    Craig Hallum
    4D Molecular Therapeutics Inc.
    $FDMT
    9/23/2024Overweight → Neutral
    Cantor Fitzgerald
    More analyst ratings

    $ACON
    $AKYA
    $CPHI
    $EVAX
    SEC Filings

    View All

    BiomX Inc. filed SEC Form 8-K: Leadership Update, Other Events

    8-K - BiomX Inc. (0001739174) (Filer)

    3/2/26 4:05:47 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Evaxion A/S

    6-K - Evaxion A/S (0001828253) (Filer)

    3/2/26 8:10:05 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Evaxion A/S

    6-K - Evaxion A/S (0001828253) (Filer)

    2/27/26 4:45:16 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $AKYA
    $CPHI
    $EVAX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Operating Officer Sabet Ahmed Zaki bought $468 worth of shares (20 units at $23.40), increasing direct ownership by 2% to 1,015 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:22:27 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Chief Operating Officer Sabet Ahmed Zaki bought $488 worth of shares (25 units at $19.50), increasing direct ownership by 3% to 995 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:21:46 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Chief Operating Officer Sabet Ahmed Zaki bought $505 worth of shares (31 units at $16.30), increasing direct ownership by 3% to 970 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:19:49 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ACON
    $AKYA
    $CPHI
    $EVAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evaxion to announce business update and full year 2025 financial results on March 5, 2026

    COPENHAGEN, Denmark, March 2, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its full year 2025 financial results on Thursday March 5, 2026, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be acces

    3/2/26 8:00:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year

    NEW HAVEN, Conn., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces some preliminary (unaudited) financials for Q4-2025 and for its fiscal year 2025. Below are some of the key financial performance metrics for the Company. Revenue Growth – Precipio's revenues increased from $18.5M in 2024 to $24.0M in 2025, an increase of 30% year over year. Q4-2025 revenues were $6.7M, an increase of 23% YoY from $5.4M in Q4-2024. Positive Adjusted EBITDA – Precipio will report Adjusted EBITDA of $0.95M for Q4-2025, and $1.23M for the full year 2025. This is compared to Adjusted EBITDA of $0.40M in Q4-2024 and ($1.5M) in full year 2024. Please

    2/25/26 9:30:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives

    WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ:HOWL) (the "Company" or "Werewolf"), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that the Company will explore a full range of strategic alternatives to advance its promising platform and drug development pipeline to maximize stockholder value. The Company has engaged Piper Sandler & Co. ("Piper Sandler") to serve as exclusive financial advisor to assist in the strategic evaluation process. "We have initiated a process to explore a ran

    2/24/26 4:09:32 PM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $AKYA
    $CPHI
    $EVAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Andrews Ronald Asbury was granted 568 shares, increasing direct ownership by 4% to 15,796 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:25:16 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Director Cohen David Seth was granted 746 shares, increasing direct ownership by 1% to 53,688 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:24:23 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Director Cossman Jeffrey was granted 597 shares, increasing direct ownership by 4% to 15,340 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:23:26 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ACON
    $AKYA
    $CPHI
    $EVAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Evaxion Biotech with a new price target

    Maxim Group initiated coverage of Evaxion Biotech with a rating of Buy and set a new price target of $10.00

    2/19/26 8:24:06 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barclays resumed coverage on 4D Molecular Therapeutics with a new price target

    Barclays resumed coverage of 4D Molecular Therapeutics with a rating of Overweight and set a new price target of $33.00

    1/28/26 7:14:57 AM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Werewolf Therapeutics downgraded by Wedbush with a new price target

    Wedbush downgraded Werewolf Therapeutics from Outperform to Neutral and set a new price target of $1.00

    12/19/25 9:28:37 AM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $AKYA
    $CPHI
    $EVAX
    Leadership Updates

    Live Leadership Updates

    View All

    ENvue Medical Appoints Industry Veteran Marc Waldman as Vice President, Commercial

    TYLER, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the appointment of Marc Waldman as Vice President, Commercial. In this role, Mr. Waldman will lead ENvue's U.S. commercialization strategy, with a focus on expanding its existing presence in 38 hospitals and accelerating revenue across the Company's enteral platform. "Marc is a highly accomplished sales leader with extensive GPO and IDN expertise and long-standing relationships th

    1/21/26 8:30:00 AM ET
    $FEED
    $NAOV
    Industrial Specialties
    Health Care

    Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

    Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companiesStrong track record of launching breakthrough technologies across spine, neurosurgery and pain managementStrengthens Aclarion's commercial execution as the Company expands adoption and payer engagement across the Eastern U.S. BROOMFIELD, Colo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the

    12/2/25 8:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

    Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class teamVIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026 ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform compa

    11/20/25 8:00:00 PM ET
    $AURA
    $FDMT
    $NBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ACON
    $AKYA
    $CPHI
    $EVAX
    Financials

    Live finance-specific insights

    View All

    Evaxion to announce business update and full year 2025 financial results on March 5, 2026

    COPENHAGEN, Denmark, March 2, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its full year 2025 financial results on Thursday March 5, 2026, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be acces

    3/2/26 8:00:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year

    NEW HAVEN, Conn., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces some preliminary (unaudited) financials for Q4-2025 and for its fiscal year 2025. Below are some of the key financial performance metrics for the Company. Revenue Growth – Precipio's revenues increased from $18.5M in 2024 to $24.0M in 2025, an increase of 30% year over year. Q4-2025 revenues were $6.7M, an increase of 23% YoY from $5.4M in Q4-2024. Positive Adjusted EBITDA – Precipio will report Adjusted EBITDA of $0.95M for Q4-2025, and $1.23M for the full year 2025. This is compared to Adjusted EBITDA of $0.40M in Q4-2024 and ($1.5M) in full year 2024. Please

    2/25/26 9:30:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Takes Major Steps Toward a Clean Balance Sheet

    NEW HAVEN, Conn., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) has made major strides in cleaning up its balance sheet with two major accomplishments: 1. Major obligation repaid A $1.1 million advance from Change Healthcare ("CHC"), the Company's clearinghouse service for billing claims processing, has been repaid. CHC experienced a cybersecurity incident in 2024 and advanced Precipio and others funds to cover collections shortfalls. In early January 2026, the Company completed its repayment of that advance. Precipio maintains a small loan with the Connecticut Department of Economic and Community Development in the approximate princ

    1/15/26 9:00:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ACON
    $AKYA
    $CPHI
    $EVAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by 4D Molecular Therapeutics Inc.

    SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)

    11/15/24 5:05:27 PM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by 4D Molecular Therapeutics Inc.

    SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)

    11/14/24 5:46:12 PM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care